How Do We Navigate the Complexities Surrounding the Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Chronic Kidney Disease?

Mayo Clin Proc. 2019 Nov;94(11):2166-2169. doi: 10.1016/j.mayocp.2019.09.014.

Authors

Sunil Bhandari¹, Marie Chadburn²

Affiliations

¹ Department of Renal Medicine, Hull University Teaching Hospitals NHS Trust, Hull York Medical School, Kingston upon Hull, UK. Electronic address: Sunil.bhandari@hey.nhs.uk.
² Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.

PMID: 31685147
DOI: 10.1016/j.mayocp.2019.09.014

No abstract available

Publication types

Editorial
Comment

MeSH terms

Angiotensin Receptor Antagonists*
Angiotensin-Converting Enzyme Inhibitors
Drug Therapy, Combination
Humans
Renal Insufficiency, Chronic*

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors

Grants and funding

MC_PC_14138/MRC_/Medical Research Council/United Kingdom